ETF Managers Group’s Atea Pharmaceuticals AVIR Stock Holding History

ETF Managers Group’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$88.6K	Buy	26,460 +5,695	+27%	+$23.1K	﹤0.01%	645
2022 Q4	$99.9K	Sell	20,765 -3,804	-15%	-$19.2K	﹤0.01%	491
2022 Q3	$140K	Sell	24,569 -1,735	-7%	-$13.3K	﹤0.01%	632
2022 Q2	$192K	Buy	26,304 +1,059	+4%	+$7.23K	0.01%	646
2022 Q1	$179K	Buy	25,245 +129	+0.5%	+$876	﹤0.01%	607
2021 Q4	$227K	Sell	25,116 -5,109	-17%	-$79.6K	﹤0.01%	607
2021 Q3	$971K	Buy	30,225 +5,822	+24%	+$161K	0.02%	274
2021 Q2	$596K	Sell	24,403 -909	-4%	-$27.3K	0.01%	453
2021 Q1	$1.42M	Sell	25,312 -13,231	-34%	-$894K	0.03%	233
2020 Q4	$1.61M	Buy	+38,543	New	+$1.24M	0.04%	212

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ETF Managers Group's AVIR Position: Q1 2023 in Review

ETF Managers Group increased its Atea Pharmaceuticals (AVIR) stake by 27% in Q1 2023, buying an estimated $23.1K and bringing the position to 26,460 shares worth $88.6K. The position accounts for ﹤0.01% of the portfolio, ranked #645.

ETF Managers Group first reported a position in AVIR in Q4 2020 and has held it in 10 quarters since. The position peaked at $1.61M in Q4 2020. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

ETF Managers Group held 26,460 shares of Atea Pharmaceuticals worth $88.6K as of Q1 2023.
ETF Managers Group bought 5,695 Atea Pharmaceuticals shares in Q1 2023, an estimated $23.1K.
Atea Pharmaceuticals made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #645 holding.
ETF Managers Group first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 10 quarters since.
ETF Managers Group's Atea Pharmaceuticals position peaked at $1.61M in Q4 2020.
130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.